Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable...

Area of Science:

• Cardiology
• Diabetology
• Pharmacology

Background:

• Diabetic patients with unstable angina or non-ST-elevation myocardial infarction face higher risks of subsequent infarction or death.
• The PRISM-PLUS study investigated the efficacy of tirofiban in managing these patients.

Purpose of the Study:

• To evaluate the benefit of tirofiban, a platelet glycoprotein IIb/IIIa inhibitor, in diabetic patients with acute coronary syndromes.
• To assess the impact of tirofiban on reducing ischemic events in this high-risk population.

Main Methods:

• Analysis of data from the PRISM-PLUS study, comparing tirofiban plus heparin versus heparin alone.
• Focus on a subgroup of diabetic patients (approximately 23% of the total cohort).
• Assessment of primary composite endpoints and specific events like myocardial infarction (MI) or death at multiple time points (2, 7, 30, 180 days).

Main Results:

• Tirofiban plus heparin showed reductions in the composite endpoint of death, MI, or refractory ischemia compared to heparin alone in diabetic patients.
• Significant reductions were observed in the incidence of MI or death at 7, 30, and 180 days (P=.005, P=.002, P=.03, respectively).
• Tests for quantitative interaction confirmed that tirofiban therapy was particularly effective in diabetic patients.

Conclusions:

• Adding tirofiban to heparin and aspirin is effective in preventing major ischemic events in diabetic patients with unstable angina and non-ST-elevation MI.
• Tirofiban therapy demonstrates a significant benefit in reducing myocardial infarction or death in this vulnerable patient group.